Retatrutide Visceral Fat: What DEXA and Imaging Sub-Studies Show About Where the Weight Comes From

Imaging sub-studies in the retatrutide program report where the weight comes from — visceral adipose tissue and liver fat — and why fat location is measured separately from total mass.

Not All Fat Is Equal: The Visceral Priority

Body composition imaging in retatrutide trials reports that weight loss is not anatomically uniform. Visceral adipose tissue (VAT) — the organ-wrapping fat depot studied in metabolic research — declined faster and further than subcutaneous fat as a fraction of baseline. Liver fat showed the largest relative change: hepatic proton-density fat fraction fell rapidly in early trial weeks, an observation researchers attribute to the glucagon-receptor component and its effect on hepatic fat oxidation. In the imaging data, subjects lose 'inside fat' before 'outside fat' changes visually.

That ordering is what makes these sub-studies notable. VAT and liver fat are the two adipose depots most frequently studied for their association with insulin resistance, dyslipidemia, and inflammation — which is why trial cardiovascular and metabolic markers moved earlier than total-mass changes alone would predict.

What the Imaging Sub-Studies Report

The imaging data across the retatrutide program reported: reductions in liver fat fraction within weeks of the first trial dose steps; VAT volumes declining ahead of total-mass proportionality; and lean mass declining too — the 25-40% lean-mass fraction reported across rapid pharmacological weight-loss studies, mitigated but not eliminated by protein intake and resistance training in the published data.

For readers tracking the same endpoints the trials use: the tape measure (iliac-crest waist) and lab work (ALT/AST, triglycerides, fasting glucose) are the values the research literature associates with the visceral axis, more than the scale is. When total mass plateaus while waist and labs continue to change, that divergence is itself a documented research observation.

Why Fat Location Is Measured Separately

In the trial literature, visceral-fat measurement drives study design. The dose-escalation steps reported in the retatrutide protocols (0.5, 1, 2, 4, 8 and 12 mg) were chosen to test whether additional receptor suppression produced additional depot-specific change — at the cost of a longer side-effect window in the reported data. Waist and laboratory endpoints are the primary visceral readouts in these sub-studies.

Retatrutide is investigational. It is not approved for human use by any regulator, no approved dosing exists, and the amounts above are reported from published trial protocols as research data — not as a schedule for anyone to follow.

📊 Dosage Calculator & Protocol Chart

Convert reported trial amounts into solution volumes for lab reference:

👉 Retatrutide Calculator — Concentration and volume conversions for reported research quantities.

👉 Full Retatrutide Research Overview — The published trial data, reported dose steps, and body-composition sub-study findings in one place.

Important Disclaimer

This article is for educational and research purposes only. Retatrutide is investigational and has not been approved by the FDA or any other regulator for human use. The information provided here is synthesized from published research, clinical trial data, and community discussions. Nothing on this page is medical advice, and no peptide discussed here is offered for human use.

Keywords: retatrutide visceral fat, GLP-1 fat distribution, liver fat retatrutide, DEXA GLP-1 sub-study, visceral fat loss peptide

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content